Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 16/20 | 0.49 |
| ▸ | CCNH | P51946 | 9/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.48 |
| ▸ | CDK9 | P50750 | 8/20 | 0.48 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.48 |
| ▸ | CCNK | O75909 | 4/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397489 | 1.00 | CDK7 (0.49) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL16665647 | 1.00 | CDK7 (0.49) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL21397206 | 1.00 | CDK7 (0.49) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL16655066 | 0.97 | CDK7 (0.53) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL16655068 | 0.97 | CDK7 (0.53) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL17688365 | 0.93 | CDK7 (0.50) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL17688419 | 0.92 | CDK7 (0.42) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL16665578 | 0.91 | HTR6 (0.46) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL18074045 | 0.91 | HTR6 (0.46) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL17688363 | 0.90 | CDK7 (0.43) | CDK7CCNHCCNT1CDK9MNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | CDK7 1/4885CCNH 32/4885CCNT1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.